Glaukos (NASDAQ: UTMD) and Utah Medical Products (NASDAQ:UTMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Glaukos and Utah Medical Products’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Glaukos $159.25 million 13.48 -$90,000.00 N/A N/A
Utah Medical Products $41.41 million 8.38 $8.50 million N/A N/A

Utah Medical Products has lower revenue, but higher earnings than Glaukos.

Institutional & Insider Ownership

69.2% of Utah Medical Products shares are owned by institutional investors. 11.6% of Glaukos shares are owned by insiders. Comparatively, 8.8% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Glaukos has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Dividends

Utah Medical Products pays an annual dividend of $1.08 per share and has a dividend yield of 1.2%. Glaukos does not pay a dividend. Utah Medical Products has raised its dividend for 7 consecutive years.

Profitability

This table compares Glaukos and Utah Medical Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Glaukos -3.49% -4.11% -3.54%
Utah Medical Products 22.52% 19.13% 16.48%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Glaukos and Utah Medical Products, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos 0 3 7 0 2.70
Utah Medical Products 0 0 0 0 N/A

Glaukos currently has a consensus price target of $58.33, suggesting a potential downside of 5.16%. Given Glaukos’ higher possible upside, equities research analysts clearly believe Glaukos is more favorable than Utah Medical Products.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California.

Utah Medical Products Company Profile

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system. It also provides umbilical vessel catheters; DIALY-NATE, a disposable peritoneal dialysis set; PALA-NATE, a silicone oral protection device; URI-CATH, a urinary drainage system; MYELO-NATE, a lumbar sampling kit; and HEMO-NATE, a disposable filter. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and UTMD supplies, and gynecologic tools; Femcare trocars and cannulae; Femcare laparoscopic instruments and accessories; and EPITOME, an electrosurgical scalpel. Further, it provides FILSHIE CLIP system, a female surgical contraception; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization; LIBERTY system to treat and control urinary incontinence in women; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other suspected abnormalities of the uterus; and LUMIN to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It markets its products to neonatal intensive care unit, labor and delivery department, women's health center in hospitals, outpatient clinics, and physician's offices. The company sells its products through customer service and sales force, independent consultants, and independent manufacturer representatives. Utah Medical Products, Inc. was founded in 1978 and is headquartered in Midvale, Utah.

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.